Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223
Awaiting development [GID-HST10019] Expected publication date: TBC
Search results
227 results
-
-
Leriglitazone for treating andrenoleukodystrophy [ID3903]
Awaiting development [GID-HST10049] Expected publication date: TBC
-
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]
Awaiting development [GID-HST10022] Expected publication date: TBC
-
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]
Awaiting development [GID-HST10039] Expected publication date: TBC
-
VTS-270 for treating Niemann-Pick type C1 (ID1267)
Awaiting development [GID-HST10020] Expected publication date: TBC
-
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]
Awaiting development [GID-HST10032] Expected publication date: TBC
-
Asfotase alfa for treating paediatric-onset hypophosphatasia (review of HST6) [ID3927]
Awaiting development [GID-HST10046] Expected publication date: 15 December 2022
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 14 July 2022.
-
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 14 July 2022.
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 20 July 2022.
-
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis [ID3787]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 12 July 2022.
-
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 12 July 2022.
-
Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 30 June 2022.
-
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when stem cell transplant is unsuitable [ID4014]
Awaiting development [GID-TA10914] Expected publication date: 01 February 2023
-
Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050]
Awaiting development [GID-TA10934] Expected publication date: TBC
-
Fordadistrogene movaparvovec for the treatment of Duchenne muscular dystrophy TS ID 10420
Awaiting development [GID-TA11044] Expected publication date: TBC
-
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome or Alström syndrome ID3947
Awaiting development [GID-TA10834] Expected publication date: TBC
-
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765
Awaiting development [GID-TA11050] Expected publication date: TBC
-
Bimekizumab for treating moderate to severe hidradenitis suppurativa TS ID 10637
Awaiting development [GID-TA11045] Expected publication date: TBC
-
Leniolisib for untreated activated phosphoinositide 3-kinase delta syndrome in people 12 years and over TS ID 10657
Awaiting development [GID-TA11046] Expected publication date: TBC
-
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683
Awaiting development [GID-TA11053] Expected publication date: TBC
-
Selpercatinib for untreated RET-positive advanced medullary thyroid cancer in people 12 years and over TS ID 10762
Awaiting development [GID-TA11047] Expected publication date: TBC
-
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763
Awaiting development [GID-TA11048] Expected publication date: TBC
-
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764
Awaiting development [GID-TA11049] Expected publication date: TBC
-
Cedazuridine–decitabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy TS ID 10605
Awaiting development [GID-TA11051] Expected publication date: TBC
-
REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443
Awaiting development [GID-TA11052] Expected publication date: TBC
-
Empagliflozin for treating chronic kidney disease TS ID 10698
Awaiting development [GID-TA11043] Expected publication date: TBC
-
Daridorexant for treating insomnia disorder [ID3774]
Awaiting development [GID-TA10888] Expected publication date: 16 August 2023
-
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping TS ID 10593
Awaiting development [GID-TA10957] Expected publication date: TBC
-
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Awaiting development [GID-TA10723] Expected publication date: TBC
-
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Awaiting development [GID-TA10728] Expected publication date: TBC
-
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]
Awaiting development [GID-TA10747] Expected publication date: TBC
-
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]
Awaiting development [GID-TA10748] Expected publication date: TBC
-
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]
Awaiting development [GID-TA10750] Expected publication date: TBC
-
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]
Awaiting development [GID-TA10741] Expected publication date: TBC
-
Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]
Awaiting development [GID-TA10821] Expected publication date: TBC
-
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]
Awaiting development [GID-TA10720] Expected publication date: TBC
-
Liposomal bupivacaine for treating postoperative pain [ID3799]
Awaiting development [GID-TA10681] Expected publication date: TBC
-
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)
Awaiting development [GID-TA10306] Expected publication date: TBC
-
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)
Awaiting development [GID-TA10426] Expected publication date: TBC
-
Rivaroxaban for treating chronic heart failure [ID1462]
Awaiting development [GID-TA10393] Expected publication date: TBC
-
Dulaglutide for treating type 2 diabetes [ID1451]
Awaiting development [GID-TA10439] Expected publication date: TBC
-
Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]
Awaiting development [GID-TA10861] Expected publication date: TBC
-
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]
Awaiting development [GID-TA10795] Expected publication date: TBC
-
Bupivacaine–meloxicam for treating postoperative pain [ID2728]
Awaiting development [GID-TA10716] Expected publication date: TBC
-
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]
Awaiting development [GID-TA10843] Expected publication date: TBC
-
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]
Awaiting development [GID-TA10848] Expected publication date: TBC
-
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]
Awaiting development [GID-TA10683] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
Awaiting development [GID-TA10895] Expected publication date: TBC